| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -194,423 | -216,054 |
| Depreciation and amortization | 69,254 | 46,514 |
| Non-cash interest | 63,866 | 61,557 |
| Amortization of deferred financing costs | 5,097 | 4,959 |
| Losses from investments in investees | -12 | -9 |
| Equity-based compensation employees and non-employees | 7,797 | 4,828 |
| Impairment of intangible assets | 1,007 | - |
| Realized gain on disposal of fixed assets and sales of equity securities | 3,846 | 3,858 |
| Change in fair value of equity securities and derivative instruments | -1,447 | -1,734 |
| Inducement expense and loss on debt conversion | 32,647 | 32,647 |
| Deferred income tax (benefit) provision | -4,850 | -23,137 |
| Gain on sale of assets | 101,576 | - |
| Accounts receivable, net | -23,504 | -19,115 |
| Inventory, net | 5,291 | 5,915 |
| Other current assets and prepaid expenses | 1,283 | 2,318 |
| Other assets | 98 | 510 |
| Accounts payable | 2,843 | 8,087 |
| Foreign currency measurement | -4,665 | -1,989 |
| Accrued expenses and other liabilities | -44,063 | -43,643 |
| Net cash used in operating activities | -152,621 | -117,974 |
| Investments in investees | 7,665 | - |
| Proceeds from sale of equity securities | 51,655 | 51,655 |
| Purchase of marketable securities | 0 | - |
| Proceeds from the sale of property, plant and equipment | 194 | 181 |
| Capital expenditures | 9,612 | 6,477 |
| Investments in investees | - | 7,665 |
| Proceeds from labcorp sales including escrow released | 197,770 | - |
| Net cash provided by investing activities | 232,342 | 37,694 |
| Issuance of 3.00 convertible senior notes, net (including related parties) | 0 | 0 |
| Issuance of 2044 notes | 0 | - |
| Debt issuance costs | 0 | 0 |
| Share repurchase | 33,533 | 18,255 |
| Proceeds from the exercise of common stock options | -123 | -123 |
| Repurchase of 2029 convertible notes | 62,208 | - |
| Borrowings on lines of credit | 24,505 | 16,636 |
| Repayments of lines of credit | 28,184 | 19,387 |
| Settlement of convertible notes | 174 | 62,382 |
| Net cash (provided by) used in financing activities | -99,717 | -83,511 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 3,255 | 3,571 |
| Net decrease (increase) in cash, cash equivalents and restricted cash | -16,741 | -160,220 |
| Cash and cash equivalents at beginning of period | 445,615 | - |
| Cash and cash equivalents at end of period | 428,874 | - |
OPKO HEALTH, INC. (OPK)
OPKO HEALTH, INC. (OPK)